Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Childhood Tuberculosis Contact Investigation and Treatment of Latent Tuberculosis Infection: a Single Center Study, 2014-2017

소아청소년 결핵 접촉자 검진 및 잠복결핵감염의 치료 현황: 2014-2017 단일 기관 연구

  • Hwang, Woo Jin (Department of Pediatrics, Chungnam National University Hospital) ;
  • Lee, Go Un (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital) ;
  • Kim, So Hyun (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital) ;
  • Cho, Eun Young (Department of Pediatrics, Chungnam National University Hospital)
  • 황우진 (충남대학교병원 소아청소년과) ;
  • 이고운 (충남대학교병원 호흡기내과) ;
  • 김소현 (충남대학교병원 호흡기내과) ;
  • 조은영 (충남대학교병원 소아청소년과)
  • Received : 2018.09.26
  • Accepted : 2018.11.23
  • Published : 2019.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In order to prevent tuberculosis transmission early, it is important to diagnose and treat tuberculosis infection by investigating people who have contact with patients with active tuberculosis. Methods: From July 2014 to June 2017, the intrafamilial childhood contacts of the patients who were diagnosed with active tuberculosis at Chungnam National University Hospital were investigated for the presence of tuberculosis infection. We also retrospectively analyzed the treatment status of children treated with latent tuberculosis infection (LTBI) during the same period. Results: Among the 269 children who had intrafamilial contact with active tuberculosis patient, 20 (7.4%) did not receive any screening. At the first screening, one (0.4%) was diagnosed with pulmonary tuberculosis, seven (2.8%) had a previous history of tuberculosis infection, and 42 patients (16.9%) were diagnosed with LTBI. At the second screening, 29 patients (11.6%) were diagnosed with LTBI, and 61 patients did not finish the investigation. Only 188 (69.9%) out of 269 patients completed the investigation. Ninety patients received treatment for LTBI and 83 patients (92.2%) completed the treatment, of which 18 patients had side effects such as rash, fatigue, and gastrointestinal symptoms. However, there were no serious side effects requiring treatment discontinuation. Conclusions: The completion rate of childhood tuberculosis contact investigation was low, but the completion rate of LTBI treatment was high in children without serious side effects. In order to prevent and manage the spread of tuberculosis, active private-public partnership efforts and education of the patient and guardian are needed.

목적: 결핵 전파를 조기에 차단하기 위해서는, 활동성 결핵 환자와 접촉한 사람들을 조사하여 결핵 질환 및 잠복결핵감염을 진단하고 치료하는 것이 매우 중요하며, 국내에서는 민간-공공협력 결핵관리사업을 통해 적극적인 접촉자 조사 활동을 지원하고있다. 본연구에서는최근 3년간단일기관에서이루어진소아청소년연령에서의접촉자검진과소아잠복결핵감염치료 현황에 대해 조사하였다. 방법: 2014년 7월 1일부터 2017년 6월 30일까지 충남대학교병원에서 활동성 결핵 환자로 진단받은 환자들을 대상으로 가족 내 소아청소년 접촉자에 대한 검진을 시행하여 접촉자 검진 완료율 및 결과를 분석하였고, 이와 함께 동일 기간 동안 잠복결핵감염으로 치료 받은 소아청소년 환자들의 치료 현황을 후향적으로 검토하였다. 결과: 연구 기간 동안 본 기관에서 활동성 결핵 환자는 총 1,002명 진단되었고, 그 중 소아청소년 가족접촉자가 있는 환자는 171명이었다. 소아청소년 접촉자 269명 중 20명(7.4%)은 검진을 전혀 받지 않았다. 1차 검진을 받은 249명 중 폐결핵이 1명(0.4%) 진단되었고, 7명(2.8%)은 과거의 결핵 감염 병력이 있었으며, 42명(16.9%)이 잠복결핵감염으로 진단되었다. 2차 검진 시 29명(11.6%)이 추가로 잠복결핵감염으로 진단되었으며, 2차 검진까지 필요하였으나 검진을 완료하지 않은 사람이 61명으로 총 접촉자 269명 중 188명(69.9%)만이 필요한 검진을 완료하였다. 잠복결핵감염으로 치료받은 소아청소년 환자는 90명이었으며 83명(92.2%)이 치료를 완료하였고, 이 중 18명이 발진(8명), 피로(5명), 위장장애(5명) 등의 부작용을 호소하였으나 치료 중단이 필요한 심각한 부작용은 없었다. 결론: 민간-공공협력 결핵관리사업 도입 및 보편화 후에도 소아청소년 연령에서의 결핵 접촉자 검진 완료율은 낮았으며, 잠복결핵감염으로 진단받은 소아의 항결핵제 치료 시 심각한 부작용의 발생 없이 투약 완료율이 높게 나타났다. 향후 결핵 전파의 예방 및 관리를 위해 더욱 적극적인 민관 협동 노력 및 환자, 보호자 교육이 필요하겠다.

Keywords

References

  1. World Health Organization. BOX 1.1. Basic facts about TB & Chapter 1. Introduction. In: Global tuberculosis report 2018 [Internet]. Geneva: World Health Organization; 2018 [cited 2018 Oct 22]: 6-7. Available from: https://www.who.int/tb/publications/global_report/en.
  2. World Health Organization. TABLE A4.1. TB incidence estimates, 2017 & TABLE A4.2. Estimates of TB mortality, 2017. In: Global tuberculosis report 2018 [Internet]. Geneva: World Health Organization; 2018 [cited 2018 Oct 22]: 245-52. Available from: https://www.who.int/tb/publications/global_report/en.
  3. Joint Committee for the Revision of Korean Guidelines for Tuberculosis; The Korean Academy of Tuberculosis and Respiratory Diseases; Korea Centers for Disease Control and Prevention. National Tuberculosis Control Program. In: Korean guidelines for tuberculosis, 3rd ed [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2017 [cited 2018 Oct 22]: 219-21. Available from: http://www.cdc.go.kr/CDC/together/CdcKrTogether0302.jsp?menuIds=HOME006-MNU2804-MNU3027-MNU2979&cid=138077.
  4. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Nelson LJ, et al. The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:278-85.
  5. Joint Committee for the Revision of Korean Guidelines for Tuberculosis; The Korean Academy of Tuberculosis and Respiratory Diseases; Korea Centers for Disease Control and Prevention. Tuberculosis in children and adolescents. In: Korean guidelines for tuberculosis, 3rd ed [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2017 [cited 2018 Oct 22]: 122-57. Available from: http://www.cdc.go.kr/CDC/together/CdcKrTogether0302.jsp?menuIds=HOME006-MNU2804-MNU3027-MNU2979&cid=138077.
  6. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392-402.
  7. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913-20. https://doi.org/10.3201/eid2111.141894
  8. Korea Centers for Disease Control and Prevention. 2018 National tuberculosis program guideline [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2018 [cited 2018 Oct 22]. Available from: http://www.cdc.go.kr/CDC/together/CdcKrTogether0302.jsp?menuIds=HOME006-MNU2804-MNU3027-MNU2979&cid=138005.
  9. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis, 2nd edition [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2014 [cited 2018 Oct 22]. Available from: http://www.cdc.go.kr/CDC/together/CdcKrTogether0302.jsp?menuIds=HOME006-MNU2804-MNU3027-MNU2979&cid=138235.
  10. Lee MH, Sung JJ, Eun BW, Cho HK. Survey of secondary infections within the households of newly diagnosed tuberculosis patients. Pediatr Infect Vaccine 2015;22:7-15. https://doi.org/10.14776/piv.2015.22.1.7
  11. Lee TJ, Kim EK, Jeong HC. Outcomes of child contact investigations of active pulmonary tuberculosis patients: a single center experience from 2012 to 2014. Pediatr Infect Vaccine 2015;22:91-6. https://doi.org/10.14776/piv.2015.22.2.91
  12. Min DH, Wy HH, Shim JW, Kim DS, Jung HL, Park MS, et al. Risk factors for latent tuberculosis in children who had close contact to households with pulmonary tuberculosis. Allergy Asthma Respir Dis 2017;5:105-10. https://doi.org/10.4168/aard.2017.5.2.105
  13. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 2009;14:1329-37. https://doi.org/10.1111/j.1365-3156.2009.02375.x
  14. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. https://doi.org/10.1086/427802
  15. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. https://doi.org/10.1086/520983
  16. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-6. https://doi.org/10.1164/rccm.200512-1953OC